Secondary Chronic Myelogenous Leukemia: A Diverse Pathogenesis?

Aguiar, Ricardo C.T.; Beitler, Beatriz; Dorlhíac-Llacer, Pedro Enrique; Chamone, Dalton F.

doi:10.1159/000204189

Cited by 12 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are case reports of secondary Ph + chronic myelogenous leukemia (CML) following exposure to radiation (e.g., survivors of the atomic bomb, 131 I treatment for thyroid cancer, and radiation for ankylosing spondylitis) and alkylating agents for malignant or nonmalignant diseases [19][20][21][22]. Most of these patients have the expected p210 bcr-abl splice usually found in CML, but there is one report of a patient with p190 bcr-abl + CML that developed after treatment of esophageal cancer with fluorouracil [23].…”

Section: Discussionmentioning

confidence: 99%

Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature

et al. 2004

View full text Add to dashboard Cite

Survivors of childhood solid tumors including Ewing sarcoma (ES) have an increased risk of secondary malignant neoplasms (SMNs) as a consequence of exposure to chemotherapy and/or radiation (see: Bhatia S, Sklar C. Nat Rev Cancer 2002;2:124-132). The most common hematologic SMNs are myelodysplasia (MDS) and acute myelogenous leukemia (AML). Acute lymphoblastic leukemia (ALL) is uncommon in this patient population, and Philadelphia chromosome positive (Ph + ) ALL in particular, is rare. We report herein two cases of young adult patients who were both diagnosed with Ph + ALL 19 years after successful treatment for ES with combined modality therapy. A review of the relevant literature follows the case reports. Am.

show abstract

Section: Discussionmentioning

confidence: 99%

Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Single cases of secondary CML have also been reported following Wilms' tumor [10], small cell lung cancer [11], acute promyelocytic leukemia [12], and following autologous peripheral blood stem cell transplantation for MALT lymphoma [13]. A patient with myasthenia gravis and a thymoma who did not respond to thymectomy, and who was treated by radiotherapy and alkylator-based chemotherapy, presented 4 years later with secondary CML that quickly evolved to blast crisis [14].…”

Section: Discussionmentioning

confidence: 99%

Favorable early response of secondary chronic myeloid leukemia to imatinib

et al. 2004

View full text Add to dashboard Cite

Second malignant neoplasms are gradually becoming a recognized long-term complication of successful cancer treatment, and they usually respond poorly to conventional therapy and have an unfavorable outcome. Chronic myeloid leukemia (CML) is a clonal panmyelopathy, rarely seen in children with a specific cytogenetic aberration-the Philadelphia chromosome. The translocation generates an aberrant tyrosine kinase, which drives the malignant process in CML and which is also the molecular target for successful treatment of CML with imatinib. It is also exceedingly rare as a secondary malignant neoplasm in both adults and children. We report two cases of secondary CML. The first occurred after successful treatment for nasopharyngeal carcinoma in a child, and the second after treatment for lymphoma in an adolescent. Both patients had an excellent response to treatment with imatinib and attained complete cytogenetic remissions. We conclude that secondary CML may respond favorably to treatment with imatinib.

show abstract

“…Other reports have noted intervals of 60–72 months [4, 5]. To our knowledge, detailed information has been given on 20 patients with treatment-related CML following anti-tumor treatment [1, 3, 6, 7]. In these patients, the median interval from initial onset of disease to the onset of CML was 66 months (18–150 months) [7].…”

Section: Discussionmentioning

confidence: 99%

“…Various diseases have been reported as primary diseases or conditions following which treatment-related CML has developed, including chronic lymphatic leukemia, acute lymphatic leukemia, malignant lymphoma, breast cancer, renal transplantation, germ cell tumor, thymoma, and esophageal cancer, ranging from hematological to solid malignancies [1, 3, 6, 7]. To our knowledge, no other reports of treatment-related CML after MFH have been published.…”

Section: Discussionmentioning

confidence: 99%

Development of Chronic Myelocytic Leukemia after Chemotherapy for Malignant Fibrous Histiocytoma

Yamamura

Yamane²,

Aoyama³

et al. 2003

Acta Haematol

View full text Add to dashboard Cite

At the age of 28, a 33-year-old male was diagnosed with malignant fibrous histiocytoma (MFH) with a primary lesion in the right maxillary sinus. Although arterial infusion chemotherapy (pirarubicin hydrochloride and carboplatin) was given, no tumor shrinkage was observed, and surgery was therefore performed to remove the tumor. Thereafter, the patient received autologous peripheral blood stem cell transplantation with high-dose chemotherapy (combination of ifosphamide, carboplatin and etoposide) as pretreatment. An increase in the peripheral leukocyte count was noted 56 months after the diagnosis of MFH was made. Cytogenetic study showed translocation (9;22)(q34;q11). Chronic myelocytic leukemia (CML) was therefore diagnosed. MFH was in a state of complete remission. The clinical course of this patient strongly suggests that this was a case of treatment-related CML that developed after chemotherapy for MFH. Treatment-related malignant blood diseases are known to include acute myelocytic leukemia and myelodysplastic syndrome, but reports of treatment-related CML are rare, although there have been some cases of treatment-related CML occurring several years after pretreatment.

show abstract

Secondary Chronic Myelogenous Leukemia: A Diverse Pathogenesis?

Cited by 12 publications

References 7 publications

Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature

Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature

Favorable early response of secondary chronic myeloid leukemia to imatinib

Development of Chronic Myelocytic Leukemia after Chemotherapy for Malignant Fibrous Histiocytoma

Contact Info

Product

Resources

About